Table 3.

Subgroup analyses of the risk of composite kidney outcomes according to baseline characteristics.

	SGLT2i (N = 2551)			GLP1RA (N = 2551)				SGLT2i vs GLP1RA
	Cumulative incidence			Cumulative incidence
	N	New events	Rate	N	New events	Rate	HR†	95% CI	P-value	P-value for interaction
Male	1429	85	5·95%	1429	114	7·98%	0·720	(0·540, 0·960)	0·025	0·403
Female	1122	68	6·06%	1122	73	6·51%	0·854	(0·611, 1·194)	0·356
Age <65	1856	106	5·71%	1898	127	6·69%	0·821	(0·630, 1·071)	0·146	0·310
Age ≥65	695	47	6·76%	653	60	9·19%	0·650	(0·443, 0·955)	0·028
Normo- to micro-albuminuria	1986	117	5·89%	1981	136	6·87%	0·806	(0·627, 1·037)	0·094	0·547
Macroalbuminuria	565	36	6·37%	570	51	8·95%	0·674	(0·434, 1·045)	0·078
eGFR <60 mL/min/1·73 m2	727	61	8·39%	743	89	11·98%	0·733	(0·526, 1·021)	0·066	0·376
eGFR ≥60 mL/min/1·73 m2	1824	92	5·04%	1808	98	5·42%	0·867	(0·648, 1·161)	0·338
With use of ACEI/ARB	1898	134	7·06%	1935	168	8·68%	0·760	(0·602, 0·959)	0·021	0·498
Without use of ACEI/ARB	653	19	2·91%	616	19	3·08%	0·849	(0·453, 1·592)	0·610
HbA1c <8%	809	38	4·70%	742	44	5·93%	0·841	(0·542, 1·305)	0·440	0·764
HbA1c ≥8%	1742	115	6·60%	1809	143	7·90%	0·750	(0·583, 0·964)	0·025

Abbreviations: HR = Hazard ratio; CI = Confidence interval; eGFR = Estimated glomerular filtration rate; ACEI/ARB = Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.

^†HR <1 indicates SGLT2i users had lower risk of kidney outcomes compared to GLP1RA users.